Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Eisai Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
MedImmune LLC
Merck Sharp & Dohme LLC
Emory University
Merck Sharp & Dohme LLC
Salubris Biotherapeutics Inc